Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has provided an update.
Shanghai Junshi Biosciences has issued a preliminary 2025 results forecast indicating strong top-line growth driven by increased sales of commercialized products, particularly domestic revenue from its flagship immunotherapy TUOYI. Operating revenue for 2025 is expected to rise about 28% year-on-year to roughly RMB2.5 billion, while R&D spending will grow modestly to around RMB1.35 billion, reflecting continued investment in its pipeline. Despite remaining loss-making, the company anticipates a significantly narrowed net loss attributable to shareholders of about RMB873 million, a reduction of nearly 32% from 2024, with similar improvements after adjusting for share-based payments and non-recurring items. The forecast underscores both improving operating leverage from TUOYI’s broad reimbursement-backed uptake and the company’s ongoing commitment to R&D, suggesting gradual movement toward improved profitability while maintaining its competitive position in China’s innovative oncology market.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$24.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company focused on the research, development and commercialization of innovative oncology therapies. Its core product, the anti-PD-1 monoclonal antibody Toripalimab Injection (TUOYI), has 12 approved indications in mainland China and is fully included in the National Reimbursement Drug List, where it is the only anti-PD-1 therapy reimbursed for renal carcinoma, triple-negative breast cancer and melanoma.
Average Trading Volume: 3,369,002
Technical Sentiment Signal: Sell
Current Market Cap: HK$39.64B
See more data about 1877 stock on TipRanks’ Stock Analysis page.